Aztreonam : It is a novel βlactam antibiotic in which the other ring is missing (hence monobactam). It inhibits gram-negative enteric bacilli and H. influenzae at very low concentrations and Pseudomonas at moderate concentrations.
MONOBACTAMS
Aztreonam
It is a novel βlactam antibiotic in which the other ring is missing (hence monobactam).
It inhibits gram-negative enteric bacilli and H. influenzae at very low concentrations and Pseudomonas at moderate concentrations, but does not inhibit gram-positive cocci or
faecal anaerobes. Thus, it is a βlactam antibiotic with a spectrum resembling
aminoglycosides. It is resistant to gram-negative βlactamases. The main
indications of aztreonam are hospitalacquired infections originating from
urinary, biliary, gastrointestinal and female genital tracts.
Lack of cross
sensitivity with other βlactam antibiotics except possibly ceftazidime
is the most prominent feature of aztreonam: permiting its use in patients allergic
to penicillins or cephalosporins. Rashes and rise in serum aminotransferases
are the notable adverse effects. It is eliminated in urine with a t½ of 1.8 hr.
Dose: 0.5–2 g i.m. or i.v.
6–12 hourly.
AZENAM, TREZAM 0.5,
1.0, 2.0 g/vial inj.
TH 2019 - 2024 pharmacy180.com; Developed by Therithal info.